002294.SZ Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (30 bal. 2024 @ 10:04):

Stats
Dzisiejszy wolumen	5.09M
Średni wolumen	5.53M
Kapitalizacja rynkowa	34.84B
EPS	CNY0.0900 ( 2024-03-25 )
Last Dividend	CNY0 ( N/A )
Next Dividend	CNY0 ( N/A )
P/E	62.59
ATR14	CNY0.0240 (0.08%)

Wolumen Korelacja

Długi: 0.00 (neutral)

Krótki: -0.98 (very strong negative)

Signal:(37.117) Neutral

Shenzhen Salubris Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Shenzhen Salubris Korelacja - Waluta/Towar

0.24
( neutral )

-0.27
( neutral )

0.00
( neutral )

-0.30
( neutral )

0.30
( neutral )

0.45
( neutral )

Shenzhen Salubris Finanse

Annual	2023
Przychody:	CNY3.32B
Zysk brutto:	CNY2.19B (66.07 %)
EPS:	CNY0.530

FY	2023
Przychody:	CNY3.32B
Zysk brutto:	CNY2.19B (66.07 %)
EPS:	CNY0.530

FY	2022
Przychody:	CNY3.48B
Zysk brutto:	CNY2.49B (71.46 %)
EPS:	CNY0.580

FY	2021
Przychody:	CNY3.06B
Zysk brutto:	CNY2.27B (74.06 %)
EPS:	CNY0.530

Financial Reports:

No articles found.

Shenzhen Salubris

Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of medicines for cardiovascular, anti-diabetic, antineoplastic, and orthopedic therapeutic in China. It offers cardiovascular and cerebrovascular products, such as allisartan isoproxil, benazepril hydrochloride, desloratadine, and clopidogrel bisulfate tablets, as well as bivalirudin and pamidronate disodium injections; recombinant SeV-hFGF2/dF Injection for the treatment of diabetic foot disease; and anti-tumor and orthopedics medicines. The company also provides anti-infection products comprising cefonicid sodium, ceftazidime, ceftriaxone sodium, cefonicid sodium, cefminox sodium, cefuroxime sodium, cefepime hydrochloride, and cefodizime sodium injections, as well as azithromycin dispersible and levetiracetam tablets. In addition, it offers biotechnological drugs, such as recombinant protein and monoclonal antibody drugs. Further, the company is involved in import, licensing-in, and licensing-out medicines for Europe markets. The company was founded in 1998 and is headquartered in Shenzhen, China.